Subject(s)
Breast Neoplasms/pathology , Carcinoid Tumor/pathology , Cell Transformation, Neoplastic/pathology , Biomarkers, Tumor/analysis , Breast/pathology , Breast Neoplasms/therapy , Carcinoid Tumor/therapy , Combined Modality Therapy , Diagnosis, Differential , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Microscopy, Electron , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapySubject(s)
Fetal Death/etiology , Infant Mortality , Female , Germany, West , Humans , Infant, Newborn , Placental Insufficiency/complications , PregnancySubject(s)
Cesarean Section , Cesarean Section/adverse effects , Female , Humans , Pregnancy , Time FactorsSubject(s)
Cesarean Section/methods , Birth Weight , Breech Presentation , Female , Fetal Hypoxia/surgery , Humans , Infant, Newborn , Obstetric Labor Complications/surgery , Placenta Previa/surgery , Postoperative Complications/etiology , Postoperative Complications/mortality , Postoperative Complications/surgery , Pregnancy , Tissue Adhesions , Uterine Rupture/surgeryABSTRACT
167 women were treated with 0.5 mg lynestrenol/day for a period of 8-32 weeks immediately postpartum. The lactation periods of 67 of the women were observed during the stay in hospital (maximum 7 days) in comparison with a control group (n = 20) of untreated women in the puerperium. There was no quantitative difference in milk production between the lynestrenol-treated women and the control group. In order to exclude a possible thromboembolic effect the lynestrenol the thrombocyte aggregation was determined in all women at 4-weekly intervals as a measure of a thrombotic tendency. During the entire period of the investigation the mean PAT rating remained between I and II. Among the clinical parameters a raised amenorrhea rate of 21% and a larger proportion (39%) of breakthrough bleedings were notable. The responded easily to treatment.
Subject(s)
Lactation/drug effects , Lynestrenol/pharmacology , Postpartum Period/drug effects , Adolescent , Adult , Cervix Mucus/drug effects , Cervix Mucus/metabolism , Female , Humans , Lynestrenol/adverse effects , Lynestrenol/metabolism , Menstruation Disturbances/chemically induced , Milk, Human/metabolism , Platelet Aggregation/drug effects , PregnancySubject(s)
Pregnancy in Diabetics , Female , Humans , Obstetric Labor Complications , Pregnancy , Prenatal CareSubject(s)
Abortion, Threatened/blood , Placental Lactogen/blood , Female , Humans , Pregnancy , Prognosis , Time FactorsABSTRACT
Radio-immunologic measurement of alpha-fetoprotein is possible in small amounts of blood and amniotic fluid. During the first half of pregnancy the AFP values in maternal serum are lowered when there is fetal abnormality (hydatid cyst, immnent abortion). In the second half of pregnancy high values of AFP also indicate danger to the fetus (Rh-incompatibility). The older the pregnancy the AFP values in amniotic fluid fall. In pathologic pregnancy (hydramnion, anencephaly, trisomy) AFP concentration was normal or raised. Measurement of the AFP level in umbilical cord -- blood provides further diagnostic chances: assessment of the duration of pregnancy and, therefore, of fetal maturity.
Subject(s)
Fetal Proteins/analysis , Pregnancy Complications/diagnosis , alpha-Fetoproteins/analysis , Abortion, Threatened/blood , Amniotic Fluid/analysis , Anencephaly/blood , Erythroblastosis, Fetal/blood , Female , Humans , Hydatidiform Mole/blood , Polyhydramnios/blood , Pregnancy , Pregnancy Complications/blood , Trisomy , alpha-Fetoproteins/bloodABSTRACT
This study confirms essentially the results of other investigators who found a good correlation between fetal risk and maternal AFP level. This adds an immuno-chemical technique to well-known methods of monitoring risk-pregnancies (ultra-sound, HPL, estrogenes) which enables us to measure a specific fetal metabolic product, alpha-feto-protein, in amniotic fluid, umbilical blood and maternal serum.
